论文部分内容阅读
1985～1991年间经皮穿刺注射乙醇(PEI)治疗伴肝硬化的肝细胞癌(HCC)207例。行 PEI 病人选择标准。1.<5.0 cm 的单发病灶或3个左右<4.0 cm 的多发结节;2.常规 B 超、CT 检查无肝外转移或门脉癌检;3.PT>40%、血小板计数>40000/μl;4.肝功 Child A 或 B 级;5.年龄<75岁;6.不能承受外科手术、拒绝手术或肝癌切除后的复发性肿瘤。本组207例中,男性161例,女46例,年龄46～7.5岁,平均83.5岁。47%的病人伴肝炎后肝硬化,32%为酒精性肝硬化,21%肝硬化的病因诊断不明。单发病灶162例,其中<3.0 cm 者86例,3～5cm 76例。多发结节45例.肝功能 Child A 级136例,B 级54例,C 级17例。30例 AFP>200 ng/ml(21例单发,9例多发).
From 1985 to 1991, 207 cases of hepatocellular carcinoma (HCC) with liver cirrhosis were treated by percutaneous ethanol injection (PEI). PEI patient selection criteria. 1. <5.0 cm single lesion or 3 multiple nodules of <4.0 cm; 2. Conventional B-ultrasonography, CT examination without extrahepatic metastasis or portal vein cancer screening; 3. PT> 40%, platelet count> 40000 / μl; 4. Liver function Child A or B; 5. Age <75 years; 6. Can not afford surgery, rejection surgery or resection of liver cancer after resection. In this group of 207 cases, there were 161 males and 46 females, aged 46-7.5 years, with an average of 83.5 years. Forty-seven percent of patients had post-hepatitis cirrhosis, 32% had alcoholic cirrhosis, and 21% had etiological diagnosis of cirrhosis. There were 162 single lesions, of which 86 were <3.0 cm and 76 were 3 – 5 cm. Multiple nodules occurred in 45 cases. Liver function was 136 cases in Child A, 54 in B, and 17 in C. 30 cases of AFP> 200 ng/ml (21 cases of single, 9 cases of multiple).